Biopharma Dealmaking Quarterly Statistics, Q2 2013

A look at the financing, M&A, and alliance activity April-June 2013

Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.

From April through June 2013, 134 financings brought in over $11 billion, a steep increase over the previous three-months’ $4.6 billion. Similar to the preceding quarter, follow-on public offerings yielded the most capital by comparison with other financing vehicles ( $3.8 billion in aggregate, or 35% of the total biopharma dollars raised. (See Exhibit 1.) Valeant Pharmaceuticals International Inc.’s $2.3 billion June FOPO, in which it sold 27 million shares at $85 apiece, [See Deal] made up 60% of the FOPO category. The quarter’s largest transaction was also done by Valeant, in June: a $3.2 billion debt offering. [See Deal] The company sold notes to VPII Escrow Corp., issuing $1.6 billion of its 6.75% senior unsecured notes due 2018 and $1.625 billion of its 7.5% senior unsecured notes due 2021. Valeant will use the proceeds to help finance its $8.7 billion acquisition of eye care specialist Bausch & Lomb Inc., [See Deal] which had planned an IPO in March, but then withdrew the offering in May. [See Deal]

Interested in getting an alert each time we publish a quarterly review of biopharma dealmaking? Click here

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.